Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Short Interest Up 57.9% in April

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 33,800 shares, an increase of 57.9% from the March 31st total of 21,400 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average trading volume of 431,700 shares, the short-interest ratio is currently 0.1 days.

Analysts Set New Price Targets

Separately, HC Wainwright reduced their target price on Phio Pharmaceuticals from $6.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, February 6th.

Phio Pharmaceuticals Price Performance

Shares of Phio Pharmaceuticals stock traded down $0.02 on Friday, hitting $0.68. The stock had a trading volume of 106,030 shares, compared to its average volume of 459,345. Phio Pharmaceuticals has a twelve month low of $0.50 and a twelve month high of $6.85. The business’s 50 day moving average is $0.80 and its two-hundred day moving average is $0.89.

Phio Pharmaceuticals (NASDAQ:PHIO) last announced its earnings results on Monday, April 1st. The company reported ($0.17) earnings per share (EPS) for the quarter. Equities research analysts expect that Phio Pharmaceuticals will post -3.56 EPS for the current year.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.